


SHEET



SLIDE




Slide : 17- Neoplasia





Doctor: Dr. Mazen






Hallmarks of Cancer
Growth









Cell signalling

1. Growth factor binding
2. Transient activation of the growth factor receptor
3. Signal transduction
4. Transcription regulation
5. Cell cycle entry & progression




Growth factors

Typically paracrine
Subverted by abnormal
stromal interaction

Autocrine = +ve feedback
loop

e.g. Glioblastoma - PDGF
Sarcomas - $TGF\alpha$



Receptors

Receptor mutations
leading to constitutive
activation


e.g. EGFR mutations in
colon/lung cancer

Receptor over-expression

e.g. EGFR Lung SCC
HER2/NEU breast



e.g. EGF
PDGF




Signal transducers

RAS

Small G protein

Most commonly mutated proto-oncogene in human tumors

Point mutations within the GTP-binding pocket or in the enzymatic region essential for GTP hydrolysis.



Signal transducers

ABL

Non-receptor associated tyrosine kinase (TK)



Internal ABL regulatory mechanism disrupted

Constitutive TK activity


Downstream RAS pathway activation

Oncogene addiction

Imatinib (Gleevec)



INACTIVE C-ABL





ACTIVE BCR-ABL



a Direct target



b Indirect target



Transcription factors

MYC

Activate/repress transcription


+CDK
-CDKI

t(8;14) MYC in Burkitt lymphoma

Amplification in breast, colon, & lung cancers

NMYC neuroblastoma
LMYC small cell lung cancer





Cyclins & CDKs


Quiescent cells G₀
induced to enter the cell
cycle by GF & ECM
integrin signalling

Cyclin+CDK=active CDK

Regulation by CDKI

Checkpoints:


- G₁-S
- G₂-M
- Metaphase



Cyclins & CDKs

Cyclin D over-expression:
 breast
 esophagus
 liver
 lymphomas
 plasma cell tumors

CDK4 amplification:
 melanomas
 sarcomas
 glioblastomas




Cyclins & CDKs


CDKN2A germline mutations:
25% of melanoma-prone kindreds

CDKN2A somatic deletion/inactivation:
pancreatic carcinomas
glioblastomas
esophageal cancers
non-small cell lung carcinomas
soft tissue sarcomas
bladder cancers



Hallmarks of Cancer
Evading Growth Inhibition





RB : Governor of the Cell Cycle

First tumor suppressor gene to be discovered


Identified in retinoblastoma patients

Chromosome 13q14

Rare disease but mechanisms learned apply to a wide range of tumors

60% sporadic rest familial AD

RB : Governor of the Cell Cycle




Knudson “two-hit” hypothesis

Two defective copies needed

Familial: -inherited
-somatic mutation

Sporadic: 2 somatic mutations



RB : Governor of the Cell Cycle


G1-S transition

Cyclin E expression control:

- E2F sequestration
- Chromatin remodelling

Rb phosphorylation control:

- Cyclin D/CDK4,6
- Phosphatases



RB mutation mimicking


Activation of CDK4
(mutation)

Over-expression of cyclin D
(translocation/ amplification)

Inactivation of CDKI (e.g. CDKN2A)
(mutation/ deletion/ epigenetics)

Oncogenic viruses (e.g. HPV E7 protein binds to Rb preventing E2F binding)

TP53 : Guardian of the genome




Li-Fraumeni syndrome

Tumor suppressor:

- Cell cycle arrest
- temporary-quiescence
- permanent-senescence
- Induce apoptosis

p53 senses:


- Anoxia
- Abnormal oncoprotein activity (e.g. MYC/RAS)
- DNA damage



TP53 : Guardian of the genome

Transcriptional targets:


- **CDKN1A (p21)**
- *GADD45*: DNA repair
- *BAX*: Channel
- *PUMA*: Bcl-2 antagonist
- **miRNA**
 - ↓ Bcl-2
 - ↓ **Cyclins**
- *MDM2* (after repair)



TP53 : Guardian of the genome

Transcriptional targets:

- *CDKN1A* (p21)
- ***GADD45*: DNA repair**
- *BAX*: Channel
- *PUMA*: Bcl-2 antagonist
- miRNA
 - ↓ Bcl-2
 - ↓ Cyclins
- *MDM2* (after repair)



TP53 : Guardian of the genome

Transcriptional targets:


- *CDKN1A* (p21)
- *GADD45*: DNA repair
- **BAX**: Channel
- **PUMA**: Bcl-2 antagonist
- miRNA
 - ↓ Bcl-2
 - ↓ Cyclins
- *MDM2* (after repair)

TP53 : Guardian of the genome

Transcriptional targets:


- *CDKN1A* (p21)
- *GADD45*: DNA repair
- *BAX*: Channel
- *PUMA*: Bcl-2 antagonist
- miRNA
 - ↓ Bcl-2
 - ↓ Cyclins


- *MDM2* (after repair)



TP53 : Guardian of the genome

Summary





TGFβ pathway signalling

Potent inhibitor of proliferation

Type II receptor mutations:

- Colon
- Stomach
- Endometrium

SMAD4 mutations:

- Pancreas


Immune evasion,
Angiogenesis, EMT

Contact Inhibition, NF2, and APC


Not fully understood


E-Cadherin homodimeric interaction

Normal cells



Transformed cells






Contact Inhibition, NF2, and APC

Neurofibromin-2 (merlin)

NF2 homozygous loss = neurofibromatosis type 2:

noncancerous tumors in the nervous system (e.g. acoustic neuromas)



Contact Inhibition, NF2, and APC

adenomatous polyposis coli

β -catenin targets:

- growth-promoting genes
Cyclin D1
MYC
- Transcriptional regulators
TWIST
SLUG/SNAIL
- ↓
- ↓ E-cadherin expression →
- ↓ Contact inhibition
- Role in **EMT**



EMT



Downregulation of E-cadherin, ZO1
Cell-cell junction dissolution

Loss of apical-basolateral cell polarity

Actin reorganization


Upregulation of metalloproteases
Increased deposition of extracellular
matrix proteins

Migration and invasion







Hallmarks of Cancer
Evasion of Cell Death



MITOCHONDRIAL (INTRINSIC) PATHWAY

DEATH RECEPTOR (EXTRINSIC) PATHWAY





Mitochondrial (intrinsic)

Mitochondrial permeability is key


controlled > 20 proteins

Cytochrome c + cofactors, activates caspase-9

Anti-apoptotic proteins are inhibited

Bcl-2 & Bcl-x_L levels are reduced

Responsible for apoptosis in most situations




DNA damage

p53 accumulation

G1 arrest

p53 absence/mutation in certain cancers



Death receptor (extrinsic)


TNF receptor family

Responsible for apoptosis of self-reactive lymphocytes and target cells of some cytotoxic T lymphocytes

Fas or FasL mutations result in autoimmune diseases

Caspase-8 may cleave and activate Bid a "BH3 sensor" activating the mitochondrial pathway

Some viruses produce homologues of FLIP



Apoptosis abnormalities

Bcl-2 over-expression:


- Follicular B cell lymphoma (85%)
- t(14;18)
- Indolent growth

Reduced CD95 levels

FLIP over-expression

IAP over-expression

Greek: auto, *self*; phagy, *eating*



- ▶ Survival mechanism/nutrient deprivation
- ▶ Organelle turnover
- ▶ Has a role in cancer (anti or pro depending on internal/external factors)
- ▶ Regulatory overlap with apoptosis
- ▶ BH3 sensor Beclin-1 can induce apoptosis or autophagy

